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Background: PinX1 (PIN2/TRF1-interacting telomerase inhibitor 1) was suggested to be correlated with tumor
progression. This study was designed to evaluate the role of PinX1 in human breast cancer.
Methods: To evaluate the function of PinX1 in breast cancer, we used a tissue microarray (TMA) of 405 human
breast cancer patients and immunohistochemistry to analyze the correlation between PinX1 expression and
clinicopathologic variables and patient survival. We also detected the abilities of cell migration and invasion in
breast cancer by performing cell migration and invasion assay, gelatin zymography and western blot analysis. Lastly,
we set up the nude mice model by Tail vein assay to exam the functional role of PinX1 in breast cancer metastasis.
Results: We found that low PinX1 expression was associated with lymph node metastasis (P = 0.002) and histology
grade (P = 0.001) in patients, as well as with poorer overall and disease-specific survival (P = 0.010 and P = 0.003,
respectively). Moreover, we identified that PinX1 inhibited the migration and invasion of breast cancer by suppressing
MMP-9 expression and activity via NF-κB-dependent transcription in vitro. Finally, our mice model confirmed that PinX1
suppressed breast cancer metastasis in vivo.
Conclusions: Our data revealed that low PinX1 expression was an independent negative prognostic factor for breast
cancer patients. These findings suggested that PinX1 might be function as a tumor metastasis suppressor in the
development and progression of breast cancer by regulating the NF-κB/MMP-9 signaling pathway, and might be a
prognostic marker as well as a therapeutic target for breast cancer.
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Breast cancer is the most common malignancy of the
female, and its survival rate falls from 90% for localized
to 20% for metastatic disease [1]. Each year there are
approximately 400 000 deaths because of breast cancer
[2]. The high mortality is related to complications of
tumor dissemination and distant metastasis. Metastasis
is a multistep process requiring cell proliferation, migration,
invasion, adhesion, vessel formation and colonization to a
secondary site [3]. Therefore, interrupting the metastatic* Correspondence: bj@xzmc.edu.cn; jnzheng@xzmc.edu.cn
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unless otherwise stated.process is a key to decreasing breast cancer mortality. Al-
terations in chromatin play a critical role in breast cancer
progression and metastasis, but the exact molecular mecha-
nisms are still limited [4].
Human telomerase is a ribonucleoprotein, mainly con-
sisting of catalytic subunit hTERT and RNA template hTR,
which involves in malignant tumor formation [5-7]. Hu-
man telomerase reverse transcriptase (hTERT), containing
two conserved N-terminal and four C-terminal domains
essential for telomerase catalytic activity, is referred as the
rate-limiting step of telomerase activation [8]. Telomerase
expression is suppressed in most normal cells, whereas
reactivated in more than 85% of human cancer cells [9,10].
In addition, the telomerase activity is regulated by telo-
meric repeat binding factor 1 (TRF1) and its associateds is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ase inhibitor and a putative tumor suppressor, firstly found
as a Pin2/TRF1-binding protein [12]. However, unlike
other TRF1-binding proteins, PinX1 is unique in that it
can also directly bind to hTERT and inhibit telomerase ac-
tivity [12].
PinX1 is a versatile gene at human chromosome 8p23,
a region frequently associated with loss of heterozygosity
(LOH) in a variety of human malignancies [13-15]. The
full-length form of PinX1 is composed of 737 bp and en-
codes a 45-KDa nucleolar protein containing 328 amino
acids [16]. It has been identified that Pinx1 deficiency
could induce telomerase activation, telomere elongation
and chromosome instability [17], whereas overexpres-
sion of PinX1 leads to a decrease in both telomerase ac-
tivity and cancer cell tumorigenicity [18,19]. LOH of
PinX1 resulted in gastric carcinoma development, which
suggested PinX1 might have a potential inhibitory role
in cancer metastasis [20]. Then increasing evidences
demonstrate that PinX1 plays a key role as a putative
tumor suppressor in human cancer progression [21-26].
However, the PinX1 expression status and its correlation
with the clinicopathological features in breast cancer
have never been investigated. In addition, the potential
molecular mechanisms underlying the role of PinX1 in
breast cancer are still unclear.
To evaluate the function of PinX1 in breast cancer, we
used a tissue microarray (TMA) of human breast cancer
patients and immunohistochemistry to analyze the cor-
relation between PinX1 expression and clinicopathologic
variables and patient survival. Furthermore, we demon-
strated that PinX1 suppressed breast cancer migration
and invasion by inhibiting the expression and activity of
MMP-9 via NF-κB-dependent transcription in vitro and
in vivo. These data suggested that PinX1 might be func-
tion as a tumor metastasis suppressor in the develop-
ment and progression of breast cancer by regulating the
NF-κB/MMP-9 signaling pathway, and might be a prog-
nostic marker as well as a therapeutic target for breast
cancer.Results
Correlation of PinX1 staining with clinicopathologic
parameters in breast cancer patients
To investigate PinX1 expression in breast cancer, im-
munohistochemistry was carried out in TMA slides
(Figure 1A). Samples with IRS 0–3 and IRS 4–12 were
classified as low and high expression of PinX1. Of the
405 breast cancer analyzed, low and high expression
of PinX1 staining were 52.3% (212/405) and 47.7%
(193/405), respectively (Table 1). We then analyzed
the correlations between PinX1 expression and char-
acteristics of the breast carcinomas, and found thatPinX1 staining was dramatically decreased in histology
grade II and III compared with histology grade I (P =
0.001, χ2 test, Table 1). We also found that PinX1 ex-
pression is significantly correlated with lymph node
metastasis (P = 0.002, χ2 test, Table 1). However, we
did not find any significant correlations between
PinX1 expression and other clinicopathologic vari-
ables, including patient age, tumor size, ER status, PR
status, HER2 status and p53 status.
PinX1 functions as an independent prognostic factor for
human breast cancer
To further study whether PinX1 expression correlates
with the survival of patients, Kaplan-Meier survival
curves were constructed using 5-year overall and
disease-specific cumulative survival to compare the
patients with high PinX1 staining to those with low
PinX1 staining (n = 236, follow-up time, 60 months).
Our data revealed that low PinX1 staining correlated
with both poorer overall and disease-specific patient
survival (P = 0.010 and P = 0.003, respectively, log-rank
test; Figure 1B & C). The 5-year overall cumulative
survival rate dropped from 65.3% in patients with high
PinX1 expression to 48.0% in those with low PinX1
expression, and the 5-year disease-specific cumulative
survival rate dropped from 78.4% in patients with high
PinX1 expression to 57.5% in those with low PinX1
expression.
Moreover, we examined whether PinX1 expression
was an independent prognostic factor for breast cancer.
The univariate Cox regression analyses revealed that
PinX1 expression was an independent prognostic marker
for breast cancer patients overall survival (hazard ratio,
0.573; 95% CI, 0.371-0.884; P = 0.012; Table 2) and
disease-specific survival (hazard ratio, 0.417; 95% CI,
0.230-0.755; P = 0.004; Table 2). In multivariate Cox re-
gression analysis, we found that PinX1 expression was
also an independent prognostic marker for both 5-year
overall survival (hazard ratio, 0.527; 95% CI, 0.404-0.656;
P = 0.027; Table 3) and disease-specific survival (hazard
ratio, 0.429; 95% CI, 0.222-0.630; P = 0.012; Table 3).
Our results definitely confirmed that low PinX1 expres-
sion is associated with poor prognosis, suggesting that
PinX1 may function as a prognostic marker for breast
cancer.
PinX1 inhibits migration and invasion of human breast
cancer cells in vitro
Because low PinX1 expression is associated with poor
prognosis, supporting PinX1 may play important roles
in one or more steps of tumor metastasis. We investi-
gated the involvement of PinX1 in breast cancer cells
migration and invasion. We transiently transfected
MDA-MB-231 and BT-549 cells with control siRNA
Figure 1 Expression of PinX1 in breast cancer tissues and associated with 5-year overall and disease-specific survival in breast cancer
patients. (A) Negative and positive staining in breast cancer tissue. Top panel, magnification × 200; bottom panel, magnification × 400. (B) Low
PinX1 expression correlated with a poorer 5-year overall cumulative survival for 236 breast cancer patients (P = 0.010, log-rank test). (C) Low PinX1
expression correlated with a poorer 5-year disease-specific cumulative survival for 208 breast cancer patients (P=0.003, log-rank test). Cum. indicates cumulative.
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plasmids, respectively. Forty-eight or twenty-four
hours after transfection, PinX1 protein was signifi-
cantly knockdown or overexpressed in cancer cells,
respectively (Figure 2A & B). In cell migration assay,
we found that the ability of cell migration was dras-
tically increased after PinX1 knockdown in both
MDA-MB-231 and BT-549 cell line (Figure 2C). In
contrast, overexpression of PinX1 inhibited cell mi-
gration (Figure 2D). Meanwhile, the results of the cell
invasion assay corresponded with the cell migration
assay (Figure 2E & F). However, overexpression or
knockdown of PinX1 had no detectable effect on the
proliferation of breast cancer cells under normal cul-
ture conditions (data not shown).PinX1 inhibits human breast cancer cells’ migration and
invasion abilities by suppressing MMP-9 expression and
activity
To investigate the mechanisms of PinX1 regulating mi-
gration and invasion in breast cancer cells, we per-
formed western blot to detect the MMPs protein levels
and gelatin zymography to observe the MMPs activity.
Our result showed that the MMP-9 expression and ac-
tivity were negatively regulated by PinX1 in MDA-MB-
231 and BT-549 cells,but not MMP-2 (Figure 3A & B &
C). So we supposed PinX1 suppress migration and inva-
sion of breast cancer cells by regulating MMP-9 expres-
sion and activity. To further validate our assumption, we
added MMP-9 inhibitor I (sc-311437, Santa Cruz) at the
same time of PinX1 siRNA transfecting into cells. As
Table 1 PinX1 staining and clinicopathological
characteristics of 405 breast cancer patients
Variables PinX1 staining
Low (%) High (%) Total P *
Age
≤50 years 99 (52.7) 89 (47.3) 188 0.906
>50 years 113 (52.1) 104 (47.9) 217
Tumor size
T1 (<2 cm) 47 (61.8) 29 (38.2) 76 0.090
T2 (2-5 cm) 148 (51.2) 141 (48.8) 289
T3 (>5 cm) 11 (39.3) 17 (60.7) 28
Lymph node metastasis
Negative 83 (43.5) 108 (56.5) 191 0.002
Positive 110 (59.5) 75 (40.5) 185
Histology grade
I 11 (30.6) 25 (69.4) 36 0.001
II 103 (50.5) 101 (49.5) 204
III 50 (68.5) 23 (31.5) 73
ER status
Negative 40 (54.8) 33 (45.2) 73 0.359
Positive 63 (48.1) 68 (51.9) 131
PR status
Negative 48 (54.5) 40 (45.5) 88 0.313
Positive 55 (47.4) 61 (52.6) 116
HER2 status
Negative 14 (66.7) 7 (33.3) 21 0.206
Positive 79 (52.0) 73 (48.0) 152
p53 status
Negative 41 (50.0) 41 (50.0) 82 0.347
Positive 52 (57.1) 39 (42.9) 91
* P values are from χ2 test.
Some cases were not available for the information.
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MMP-9 inhibitor I (Figure 3D & E). We also validated
this hypothesis by migration and invasion analysis, the
migration and invasion ability can be enhanced by
knocking down PinX1 in MDA-MB-231 and BT-549
cells, nevertheless, these regulations were blocked by
MMP-9 inhibitor I (Figure 3F & G).
As we know TIMP-1 and TIMP-2 is the tissue inhibi-
tor of MMP-9 and MMP-2, so we detected the expres-
sion of TIMP protein. Our data showed that MMP-9
expression was up-regulated or down-regulated corre-
sponded with PinX1 knockdown or overexpression,
however, the expression of TIMP-1 had not changed
correspondingly. Moreover, neither overexpressing nor
silencing PinX1 had any effect on the protein levels of
MMP-2 and TIMP-2 (Figure 3A & B).PinX1 suppress MMP-9 expression via NF-κB-dependent
transcription
Furthermore, increasing evidence demonstrate that sev-
eral MMPs (including MMP-9) expression and activa-
tion were regulated by NF-κB activation in many human
cancers [27,28]. G-patch domain of PinX1 is also an im-
portant nucleic acids binding domain which could com-
bine with the C-terminus of the NF-κB-repression factor
(NRF) [29]. Thus, PinX1 may also inhibit the transcrip-
tional activity of NF-κB proteins by direct protein-
protein interaction with its G-patch domain. Western
blot results showed that the level of NF-κB-p65 protein
was dramatically increased in PinX1KD-MDA-MB-231
cells and PinX1KD-BT-549 cells. In contrast, NF-κB-p65
expression was down-regulated sharply in PinX1OE-MDA-
MB-231 cells and PinX1OE-BT-549 cells (Figure 4A & B).
To further confirm whether PinX1 regulated MMP-9 ex-
pression via the NF-κB signaling pathway in human breast
cancer cells, we transfected NF-κB-p65 siRNA (Santa
Cruz) into PinX1KD-MDA-MB-231 cells and PinX1KD-BT-
549 cells. Our result indicated that the MMP-9 expression
was up-regulated in PinX1KD-MDA-MB-231 cells and
PinX1KD-BT-549 cells, but these effects were further
blocked by silencing NF-κB-p65 with the specific siRNA
(Figure 4A & B). These data provide definite evidence that
PinX1 may modulate MMP-9 expression by NF-κB tran-
scription factor.
We also validated the mechanism by migration and in-
vasion analysis. The migration and invasion ability can
be enhanced in PinX1KD-MDA-MB-231 cells and
PinX1KD-BT-549 cells, however, these effects were dra-
matically reversed by treatment with NF-κB-p65 siRNA
(Figure 4C & D). These data suggested that PinX1 may
regulate the migration and invasion via the NF-κB/
MMP-9 signaling pathway.
PinX1 inhibits breast cancer cells metastasis in vivo
Lastly, we examined whether PinX1 suppressed breast can-
cer metastasis in vivo. PinX1OE-MDA-MB-231, PinX1KD-
MDA-MB-231 and Ctrl-MDA-MB-231 cell lines were
established previously. After 3 weeks selection following
with lentivirus infection, the PinX1 protein levels of these
cell lines were confirmed by western blot. Then continuing
to incubate them without adding puromycin for 2 months,
we determined that the PinX1 protein expression levels of
three stable cell lines had not been changed (Figure 5A).
The BALB/c nude mice were randomly divided into
three groups: PinX1OE, PinX1KD and Control group,
each group consisted of 10 mice. Three groups of nude
mice were injected through tail vein with PinX1OE-
MDA-MB-231, PinX1KD-MDA-MB-231 and Ctrl-MDA-
MB-231 cells respectively. After 2 months, three groups
of mice were sacrificed and their lungs were resected
and fixed in 10% buffered formalin for metastatic
Table 2 Univariate Cox proportional regression analysis on 5-year overall and disease-specific survival of 405 breast
cancer patients
Variable*
Overall survival Disease-specific survival
Hazard ratio 95% CI† P* Hazard ratio 95% CI† P*
PinX1
Low 1.000 0.012 1.000 0.004
High 0.573 0.371-0.884 0.417 0.230-0.755
Age
≤50 years 1.000 0.443 1.000 0.630
>50 years 0.864 0.594-1.225 0.855 0.632-1.030
Tumor size
≤5 cm 1.000 0.002 1.000 0.000
>5 cm 2.289 1.363-3.843 3.463 2.730-3.935
Lymph node metastasis
Negative 1.000 0.000 1.000 0.000
positive 4.994 3.032-8.227 3.564 2.594-4.505
Histology Grade
I 1.000 0.002 1.000 0.005
II/III 2.309 1.740-3.456 2.554 1.618-3.551
* P values are from Log-rank test.
† CI: confidence interval.
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Randomly selected metastatic nodules had been vali-
dated by H&E staining (Figure 5B). Extensive tumor for-
mation was found in PinX1KD group. In contrast, the
lungs in PinX1OE group had fewer and smaller detectable
tumor nodules (Figure 5C). Compared with PinX1OE
group, the dramatic increase in the number of the tumor
nodules was observed in PinX1KD group, meanwhile, Pin-
X1OE group and PinX1KD group had significant differences
compared with Control group respectively (Figure 5D).
Discussion
PinX1 is a functional gene at human chromosome 8p23,
a region frequently associated with loss of heterozygosity
(LOH) in a variety of human malignancies [13]. Increasing
evidence demonstrate that PinX1 plays a key role as a pu-




Hazard ratio 95% CI†
PinX1 0.527 0.404 to 0.656
Age 0.993 0.740 to 1.345
Tumor size 2.730 1.947 to 3.785
Lymph node metastasis 3.183 1.911 to 4.505
Histology Grade 1.840 1.184 to 2.843
*Coding of variables: PinX1 was coded as 1 (low), and 2 (high). Age was coded as 1 (≤5
Lymph node metastasis was coded as 1 (negative), and 2 (positive). Histology grade w
† CI: confidence interval.[18,19]. However, the expression and function of PinX1 in
breast cancer and its correlation with the clinicopathologi-
cal features of breast cancer patients have never been
investigated.
In the present study, we used a breast cancer TMA
containing 405 tumor samples with specific clinical data
to investigate the role of PinX1 in human breast cancer.
Our data showed that low PinX1 expression was associ-
ated with lymph node metastasis and histology grade in
patients, as well as with poorer overall and disease-
specific survival (Figure 1B & C; Table 1). Cox regression
analysis revealed that low PinX1 expression was an inde-
pendent negative prognostic indicator for breast cancer
patients (Table 2; Table 3). These findings suggested a
potential role of PinX1 in regulating breast cancer me-
tastasis and functioning as a breast cancer candidate
clinical prognostic marker. Our clinical data urged us tol and disease-specific survival of 405 breast cancer
Disease-specific survival
P Hazard ratio 95% CI P
0.027 0.429 0.222 to 0.630 0.012
0.836 0.856 0.652 to 1.222 0.884
0.003 2.913 1.882 to 4.146 0.001
0.001 3.962 2.975 to 4.756 0.000
0.023 1.958 1.514 to 2.511 0.032
0 years), and 2 (>50 years). Tumor size was coded as 1 (≤5 cm), and 2 (>5 cm).
as coded as 1 (I), and 2 (II and III).
Figure 2 PinX1 inhibits migration and invasion of human breast cancer cells. (A) Western blot analysis of the relative protein level of PinX1
in PinX1 knockdown (siPinX1) and control siRNA (siCtrl) groups for both MDA-MB-231 and BT-549 cell lines. (B) Western blot analysis of the relative protein
level of PinX1 in PinX1 overexpression (PinX1OE) and control vector (Vector) groups for both MDA-MB-231 and BT-549 cell lines. (C) and (E) PinX1
knockdown significantly inhibited migration and invasion abilities of MDA-MB-231 and BT-549 cells. (D) and (F) PinX1 overexpression significantly
inhibited migration and invasion abilities of MDA-MB-231 and BT-549 cells. All experiments were carried out in triplicate. Data are shown as means ±
SD. ***, P < 0.001.
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Figure 3 PinX1 inhibits migration and invasion of breast cancer cells by suppressing MMP-9 expression and activity. (A) Western blot
analysis of the relative protein levels of PinX1, MMP-2, MMP-9, TIMP-1 and TIMP-2 in PinX1 siRNA and control siRNA group for both MDAMB-231
and BT-549 cell lines. (B) Western blot analysis of the relative protein levels of PinX1, MMP-2, MMP-9, TIMP-1 and TIMP-2 in PinX1OE and Vector
groups for both MDA-MB-231 and BT-549 cell lines. (C) Top panel, gelatin zymography analysis of the relative enzyme activities of MMP-9 in PinX1
knockdown and control siRNA group for both MDA-MB-231 and BT-549 cell lines. Bottom panel, gelatin zymography analysis of the relative
enzyme activities of MMP-9 in PinX1OE and Vector groups for both MDA-MB-231 and BT-549 cell lines. (D) Western blotting of PinX1 and
MMP-9 in there groups of control siRNA, PinX1 siRNA, and PinX1 siRNA co-treated with MMP-9 inhibitor I for both MDA-MB-231 and BT-549
cell lines. (E) Gelatin zymography analysis of MMP-9 in there groups of control siRNA, PinX1 siRNA, and PinX1 siRNA co-treated with MMP-9 inhibitor I
for both MDA-MB-231 and BT-549 cell lines. (F) and (G) The increased abilities of migration and invasion regulated by PinX1 knockdown in breast cancer
cells was blocked by MMP-9 inhibitor I. All experiments were carried out in triplicate. Histograms represent means ± SD. ***, P < 0.001.
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Figure 4 PinX1 suppress MMP-9 expression via NF-κB-dependent transcription. (A) and (B) Western blot analysis of the relative protein
levels of PinX1, MMP-9 and NF-κB-p65 in four groups of control, PinX1OE , PinX1KD and PinX1KD co-treated with NF-κB-p65 siRNA for both MDA-MB-231
and BT-549 stable cell lines. The NF-κB specific siRNA dramatically prevented the up-regulation of MMP-9 expression induced by PinX1 knockdown. (C)
and (D) The increased ability of migration and invasion regulated by PinX1 knockdown was suppressed by NF-κB-p65 siRNA in both MDA-MB-231 and
BT-549 stable cell lines. All experiments were carried out in triplicate. Histograms represent means ± SD. ***, P < 0.001.
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explore the potential mechanisms.
The matrix metalloproteinase (MMP) family can de-
grade the extracellular matrix (ECM) in the major early
stages of a number of malignant tumors, which plays an
important role in cancer invasion and metastasis [30].
High expression of MMP-9 and MMP-2 were associated
with lymph node metastasis as well as with poorer sur-
vival in breast cancer [31]. Our data demonstrated that
PinX1 inhibited breast cancer cells’ migration and inva-
sion abilities by down-regulating MMP-9 expression and
activity in vitro (Figure 2; Figure 3). MMPs activity is
controlled by specific, endogenous tissue inhibitors of
metalloproteinases (TIMPs), and the imbalance between
MMPs and TIMPs is responsible for cancer metastasis
[32]. TIMP-1 is the tissue inhibitor of MMP-9, which
negatively regulating MMP-9 enzyme activity were in-
volved in several tumor metastasis processes, including
breast cancer [33]. But in our study, TIMP-1 expression
was not seemed to be the regulator of MMP-9 activation
in breast cancer cells (Figure 3A & B). These result sug-
gested us to investigate the potential mechanism of how
PinX1 regulates MMP-9 expression and activity.NF-κB is a critical transcription factor activated in
various types of human cancers and plays a crucial role
in tumor development and progression [34,35]. The NF-
κB signaling modulates several key biological processes
during the development and progression of cancer by in-
ducing transcription of a variety of target genes that
regulate cell proliferation, survival, invasion and angio-
genesis [36-38]. NF-κB is constitutively present in cells
as a heterodimer, consisting of a p50 DNA-binding sub-
unit and a p65 transactivating subunit [39]. Furthermore,
increasing evidence demonstrate that MMP-9 expression
and activation were regulated by p65 up-regulation and
nuclear translocation which induced NF-κB activation in
many human cancers [27,28]. Our data indicated that
the NF-κB specific siRNA dramatically prevented the
up-regulation of MMP-9 expression induced by PinX1
knockdown (Figure 4A & B). Consistently, the increased
ability of migration and invasion induced by PinX1
knockdown was also suppressed by inhibition of NF-κB-
p65 expression in breast cancer cells (Figure 4C & D).
Thus, these results suggested that PinX1 may regulate
the migration and invasion via the NF-κB/MMP-9 sig-
naling pathway.
Figure 5 PinX1 inhibits breast cancer cells metastasis in vivo. (A) Left panel, Western blotting of PinX1 in there groups of Ctrl-MDA-MB-231
cell lines, PinX1OE-MDA-MB-231 cell lines and PinX1KD-MDA-MB-231 cell lines, which was selected with puromycin for 2 weeks after lentivirus
infection. Right panel, without puromycin selection for 2 months, PinX1 expression levels were not changed in MDA-MB-231 stable cell lines.
(B) H&E staining sections of lungs 2 months after injection of PinX1KD-MDA-MB-231 cell lines in BALB/c nude mouse through tail vein. Left
panel, magnification × 100; right panel, magnification × 400. (C) Representative images of 10% buffered formalin fixed lungs with metastatic
nodules 2 months after injection of Ctrl, PinX1OE and PinX1KD MDA-MB-231 stable cell lines. Arrows indicate metastatic nodules. (D) The number of
lung metastatic nodules was counted under a dissecting microscope. Compared with the PinX1OE group, a statistically dramatic increase in the number
of the lung metastases was seen in PinX1KD group, and these two groups also had significant diversity compared with Ctrl group respectively. Data are
displayed with means ± SD from 10 mice in each group. ***, P < 0.001.
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anism between PinX1 and NF-κB pathway, however, we
have found some conceivable relations between them.
Human PinX1 protein contains an N-terminal Gly-rich
patch (G-patch) and a C-terminal TID (telomerase in-
hibitory domain) [12]. G-patch domain existed in a
number of putative RNA-binding proteins involved in
tumor suppression and DNA-damage repair [40], but
the function of them had been researched rarely.
Moreover, G-patch domain of PinX1 is also an im-
portant nucleic acids binding domain which could
combine with the C-terminus of the NF-κB-
repression factor (NRF) [29]. NRF is a nuclear inhibi-
tor of NF-κB, which can inhibit the transcriptional
activity of NF-κB proteins by direct protein-protein
interaction [41]. Thus, we conclude that PinX1 also
can inhibit the transcriptional activity of NF-κB pro-
teins by direct protein-protein interaction with its G-
patch domain (Figure 6). These hypothesizes have
never been definitely validated. However, the associ-
ation between PinX1 and NF-κB in breast cancer cells
exists indeed. So we will investigate the furthermolecular mechanisms between PinX1 and NF-κB
signaling pathway continually.
To further observe the functional role of PinX1 in
breast cancer metastasis in vivo, three groups of nude
mice experimental model were constructed. We investi-
gated that PinX1 overexpression in breast cancer cells sig-
nificantly inhibited the formation of metastasis nodules in
lung of nude mice. In contrast, PinX1 knockdown dramat-
ically enhanced the metastasis process (Figure 5).
In conclusion, loss of PinX1 expression was signifi-
cantly correlated with breast cancer progression and was
an independent negative prognostic factor in breast can-
cer patients. PinX1 suppressed breast cancer migration
and invasion by inhibiting the expression and activity of
MMP-9 via NF-κB-dependent transcription. Therefore
PinX1 may be an attractive therapeutic target for the
treatment of breast cancer.
Materials and methods
Patient specimens and tissue microarray construction
The collection of patient specimens and construction of
the tissue microarray (TMA) have been previously
Figure 6 A Model of PinX1 suppresses MMP-9 expression via NF-κB signaling pathway. We speculate that PinX1 can suppress the expression
of MMP-9 owing to the inhibition of transcriptional activity of NF-κB p65 proteins by direct protein-protein interaction with its G-patch domain which
could combine with the C-terminus of the NF-κB-repression factor (NRF).
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405 consecutive cases of primary breast carcinoma, from
The First Affiliated Hospital of Nanjing Medical Univer-
sity, between 1996 and 2005. All these patients were
treated with surgery only or with postoperative adjuvant
therapy. The patients’ clinicopathologic information in-
cluding age at diagnosis, tumor size, histology grade,
lymph node metastasis, ER status, PR status, HER2 sta-
tus and p53 status was obtained from the archive of the
pathology department and confirmed by the medical
record of the hospital. The histologic grade was assessed
using Bloom-Richardson classification. Five-year clinical
follow-up results were available for 236 patients. The
use of these tissue specimens was approved by the Ethics
Committee of the Hospital.Immunohistochemistry of TMA
Immunohistochemistry was carried out as described before
[43]. According to the streptavidin-peroxidase (Sp) method
using a standard Sp Kit (Zhongshan biotech, Beijing,
China). The TMA slides were dewaxed at 60°C for 20 min
followed by three 5-min washes with xylene. The tissues
were then rehydrated by washing the slides for 5-min each
with 100%, 95%, 80% ethanol and finally with distilled
water. The slides were then heated to 95°C for 30 min in
10 mmol/L sodium citrate (pH 6.0) for antigen retrieval
and then treated with 3% hydrogen peroxide for 1 hour to
block the endogenous peroxidase activity. Then subse-
quently the TMA slides were incubated with a polyclonal
rabbit anti-PinX1 antibody (1:50 dilution; Novus Biologi-
cals, Littleton, CO, USA) at 4°C overnight, and 3, 3′-diami-
nobenzidine (DAB; Zhongshan Biotech, Beijing, China)
was used to produce a brown precipitate. Negative controls
were performed by substituting primary antibodies with
non-immune serum.Evaluation of immunostaining
The evaluation of PinX1 staining was blindly and inde-
pendently examined by two pathologists. Positive PinX1
immunostaining is defined mainly in the nucleus area
and also can be observed in the cytoplasm. We grade it
according to both the intensity and percentage of cells
with positive staining. The PinX1 staining intensity was
scored 0 to 3 (0 = negative; 1 = weak; 2 =moderate; 3 =
strong). The percentage of PinX1-positive stained cells
was also scored into four categories: 1 (0%-25%), 2 (26%-
50%), 3 (51%-75%) and 4 (76%-100%). The level of PinX1
staining was evaluated by the immunoreactive score
(IRS), which is calculated by multiplying the scores of
staining intensity and the percentage of positive cells.
Based on the IRS, the PinX1 staining pattern was cate-
gorized as negative (IRS: 0), weak (IRS: 1–3), moderate
(IRS: 4–6) and strong (IRS: 8–12). The concordance for
IRS staining score of PinX1 between the two patholo-
gists was 363 in 405 samples (90%), and the few discrep-
ancies were resolved by consensus using a multihead
microscope.
The optimum cutoff value of IRS was obtained by
receiver-operator characteristic analysis, and the areas
under the curves at different cutoff values of the PinX1
IRS for 1, 3 and 5 years of overall survival time were also
calculated. The optimum value of cutoff point of the
PinX1 IRS was shown to be 3 since it had the best pre-
dictive value for survival (Additional file 1: Figure S1).
Under these conditions, samples with IRS 0–3 and 4–12
were classified as having low or high expression of
PinX1, respectively.
Animals and cell lines
Female BALB/c nude mice, 6 weeks old, were purchased
from the Shanghai Laboratory Animal Center (Shanghai,
China) for studies approved by the Animal Care Committee
Shi et al. Molecular Cancer  (2015) 14:66 Page 11 of 13of Xuzhou Medical College. Two human breast cancer cell
lines MDA-MB-231 and BT-549 were purchased from the
Shanghai Institute of Biochemistry and Cell Biology, Chin-
ese Academy of Sciences (Shanghai, China). MDA-MB-231
cells were cultured in Leibovitz’ s L-15 Medium (Gibco,
USA) supplemented with 10% fetal calf serum (Gibco,
USA), BT-549 cells were cultured in RPMI 1640 Medium
(Invitrogen, Shanghai, China) supplemented with 10% fetal
calf serum. These two cells were both incubated in a 37°C
humidified incubator with 5% CO2.siRNA and DNA transfections, and stable cell line
generation
Cells were grown to 50% confluence before small inter-
fering RNA (siRNA) transfection. PinX1 siRNA (Gene-
Pharma, Shanghai, China), NF-κB-p65 siRNA (Santa
Cruz, CA, USA) or Nonspecific control siRNA (Gene-
Pharma, Shanghai, China) was transfected by siLentFect
Lipid Reagent (Bio-Rad, CA, USA) according to the
manufacturer’s protocol. The pEGFP-C3 and pEGFP-C3-
PinX1 expression plasmids were obtained from Dr Xiao-
Fen Lai (Southern Medical University, Guangzhou,
China). Transfection of the pEGFP-C3-PinX1 plasmid
and the pEGFP-C3 vector into the MDA-MB-231 and
BT-549 cells were carried out using Lipofectamine 2000
transfection reagent (Invitrogen) following the manufac-
turer’s instructions.
PinX1 overexpression MDA-MB-231 cell lines (Pin-
X1OE-MDA-MB-231), PinX1 knockdown MDA-MB-231
cell lines (PinX1KD-MDA-MB-231) and control MDA-
MB-231 cell lines (Ctrl-MDA-MB-231) were established
by infecting with lentivirus packing PinX1 expression
vector, PinX1 shRNA expression vector and control vec-
tor respectively (GenePharma, Shanghai, China). It is the
same as the construction of PinX1 overexpression BT-
549 cell lines (PinX1OE-BT-549), PinX1 knockdown BT-
549 cell lines (PinX1KD-BT-549) and control BT-549 cell
lines (Ctrl-BT-549). Target cells were infected with lenti-
virus for 48 hours then selected with puromycin (Santa
Cruz) for three weeks.Western blot analysis
Western blot analysis was performed as described pre-
viousely [44]. The following antibodies were used for
western blot: rabbit anti-PinX1 (Novus Biologicals);
rabbit anti-MMP-2, anti-MMP-9, anti-TIMP-1, anti-TIMP-
2 (all from Cell Signaling Technology); rabbit anti-NF-κB-
p65 (Santa Cruz Biotechnology); mouse anti-β-actin (Cell
Signaling Technology); Infrared IRDye-labeled secondary
antibody (LI-COR, NE, USA) was applied to the blot for
2 hour at room temperature, the signals were detected with
Odyssey Infrared Imaging system (LI-COR).Cell migration and invasion assay
Cell migration and invasion assay were performed using
modified two-chamber plates with a pore size of 8 μm.
The transwell filter coating with or without Matrigel
(BD Biosciences, Mississauga, Canada) were used re-
spectively for invasion and migration assay. The detailed
conditions were described previously [45].Gelatin zymography
Gelatin zymography was performed as described before
[46]. Thirty-six hours after transfection, cells were incu-
bated in serum-free medium for 24 h. The proteins in
the conditioned medium were concentrated with Ami-
con Ultra-4-30 k centrifugal filters (Millipore, MA, USA)
at 7500 g for 20 min at 4°C. Fifty micrograms of the proteins
were loaded on a 10% polyacrylamide gel containing 0.1%
gelatin (Sigma, MO, USA). Gelatinolytic activity was shown
as clear areas in the gel. Gels were photographed and then
quantitatively measured by scanning densitometry.
Tail vein assay of metastasis
The BALB/c nude mice were randomly divided into
three groups: PinX1OE, PinX1KD and Control group,
each group consisted of 10 mice. The mice were injected
intravenously with 2.5 × 106 MDA-MB-231 cells in 200 μl
of PBS through tail vein. After 2 months, the three groups
of mice were sacrificed, their lungs were resected and
fixed in 10% buffered formalin for metastatic nodules
counting and further histopathological analysis. The num-
ber of metastatic nodules presented on the surface of each
group of lungs was counted by visual inspection using a
stereoscopic dissecting microscope.
Statistical analysis
For the TMA, statistical analysis was performed with
SPSS 20 software (SPSS, Inc, Chicago, IL). The associ-
ation between PinX1 staining and the clinicopathologic
parameters of the breast cancer patients was evaluated
by χ2 test. The Kaplan-Meier method and log-rank test
were used to evaluate the correlation between PinX1 ex-
pression and patient survival. Cox regression model was
used for multivariate analysis. Data are expressed as the
means ± SD. Two-factor analysis of variance procedures
and the Dunnett’s t-test were used to assess differences
within treatment groups. Differences were considered
significant when P < 0.05.
Additional file
Additional file 1: Figure S1. Receiver operating characteristic (ROC)
curve is obtained to determine the optimal cutoff value of PinX1
expression. ROC obtains the area under the curves (AUCs) at different
Shi et al. Molecular Cancer  (2015) 14:66 Page 12 of 13cutoff values of PinX1 immunoreactivity score (IRS) for 1, 3 and 5 years of
overall survival time.
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